United States · FDA National Drug Code directory
Xerava
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 71773-100_a3d105c1-c9b1-42ce-942d-34e63fdf5d83
- Product NDC
- 71773-100
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- eravacycline
- Labeler
- Tetraphase Pharmaceuticals, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20180910
- Source listing expiry
- 20271231
Source-listed ingredients
- ERAVACYCLINE DIHYDROCHLORIDE — 100 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 12 CARTON in 1 PACKAGE (71773-100-12) / 1 VIAL, GLASS in 1 CARTON (71773-100-05) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS · 71773-100-12
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →